Masahiro Kitada, Satoshi Hayashi, Yoshinari Matsuda, Kei Ishibashi, Keisuke Oikawa, Naoyuki Miyokawa

1Department of Surgery,

2Department of Clinical Pathology, Asahikawa Medical University, Asahikawa Hokkaido 078-8510, Japan

Erratum to spindle cell carcinoma of the breast as complex cystic lesion: a case report

Masahiro Kitada1, Satoshi Hayashi1, Yoshinari Matsuda1, Kei Ishibashi2, Keisuke Oikawa2, Naoyuki Miyokawa2

1Department of Surgery,

2Department of Clinical Pathology, Asahikawa Medical University, Asahikawa Hokkaido 078-8510, Japan

In the published article1, two errors appeared on page 132.e legends of Figure 7 and Figure 8 should have read as follows:

Figure 7 Immunohistological fi ndings of the positive staining for cytokeratin (AE1/AE3) (IHC staining, ×100).

Figure 8 Immunohistological fi ndings of the positive staining for vimentin (IHC staining, ×100).

1. Kitada M, Hayashi S, Matsuda Y, Ishibashi K, Oikawa K, Miyokawa N. Spindle cell carcinoma of the breast as complex cystic lesion: a case report. Cancer Biol Med 2014;11:130-133.Cite this article as:Kitada M, Hayashi S, Matsuda Y, Ishibashi K, Oikawa K, Miyokawa N. Erratum to spindle cell carcinoma of the breast as complex cystic lesion: a case report. Cancer Biol Med 2014;11:216. doi: 10.7497/ j.issn.2095-3941.2014.03.008

ABOUT THE JOURNAL

Cancer Biology & Medicine is a peer-reviewed open-access journal sponsored by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

· Cancer genetics

· Cancer and stem cell biology

· Molecular and clinical immunology

· Cancer prevention and epidemiology

· Cancer biomarkers

· Radiation oncology

· Oncology clinical trials

我國(guó)的公共決策機(jī)制是與人民當(dāng)家作主的民主政治制度相適應(yīng)的，同時(shí)也是社會(huì)環(huán)境和國(guó)家治理模式共同作用的結(jié)果。堅(jiān)持人民立場(chǎng)，充分保證人民參與和制定政策的權(quán)利，不斷維護(hù)和增進(jìn)人民利益。經(jīng)過(guò)新民主主義革命，在馬克思主義的指導(dǎo)下，不斷總結(jié)黨和人民的實(shí)踐經(jīng)驗(yàn)，我國(guó)建立起以中國(guó)共產(chǎn)黨的領(lǐng)導(dǎo)為核心，人民代表大會(huì)制度、政治協(xié)商制度、基層群眾自治制度、民族區(qū)域自治制度為基礎(chǔ)的社會(huì)主義多元民主參與機(jī)制，以中國(guó)特色社會(huì)主義法律體系為保障的監(jiān)督機(jī)制的“一核多元”格局的公共決策機(jī)制，但由于民主政治制度發(fā)展不充分，機(jī)制的作用沒有充分發(fā)揮，制度潛能沒有充分釋放。

· Mechanisms of drug sensitivity and resistance

· Targeted therapy and immunotherapy

· Multidisciplinary treatment and personalized medicine

The journal adheres to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Commitiee for Medical Journal Editors (ICMJE) and the guidelines of Committee on Publication Ethics (COPE).

MISSION

Cancer Biology & Medicine is dedicated to presenting cuttingedge and high quality articles on basic, translational, and clinical cancer research, in an effort to keep cancer researchers and clinicians updated with current knowledge of novel fi ndings and recent advances in oncology throughout the world.

AUDIENCE

Cancer Biology & Medicine endeavors to appeal to a diverse audience engaged in cancer research and subspecialties in clinical oncology. Readers may include, but are not limited to, investigators, physicians, surgeons and nurses in cancer research areas, medical students, and other relevant health care professionals.

CONTENT CATEGORIES

Original Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, Practice Guideline, Meeting Report, Case Report, and UICC-China Spoke News.

INDEXING INFORMATION

Cancer Biology & Medicine is indexed in PubMed, BIOSIS Previews, EMBASE, SCOPUS, EBSCO, Index Copernicus, DOAJ, and Chemical Abstracts.

EDITORIAL POLICIES

Authorship and Contributorship

Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) fi nal approval of the version to be published. The corresponding author is required to ensure that authors are appropriately listed and provide information on the specific contributions each author has made to the article. The manuscript’s content and its submission for publication should be approved by all authors. Contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please be aware that all communications during the submission and publishing process will be sent to the corresponding author.

Ethics Involving Humans and Animals

Experiments on human subjects should follow the ethical standards of the responsible committee on human research (institutional and national) and the Helsinki Declaration (as revised in 2008). Written informed consent should be obtained from all participants. Animal experiments should abide by the institutional and national guide for the care and use of laboratory animals. Cancer Biology & Medicine requires a statement in the Materials and Methods section that the committee of Institutional Review Board has approved the experiments and con fi rmed that all procedures comply with the relevant ethical standards.

Conflict of Interest

Con fl ict of interest exists when an author (or the author’s institution), reviewer, or editor has any fi nancial or personal

tum to: Cancer Biol Med 2014;11:130-133.

10.7497/j.issn.2095-3941.2014.02.008

Masahiro Kitada

E-mail: k1111@asahikawa-med.ac.jp

Received July 15, 2014; accepted August 1, 2014. Available at www.cancerbiomed.org

Copyright ? 2014 by Cancer Biology & Medicine